JP2018536697A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536697A5
JP2018536697A5 JP2018534025A JP2018534025A JP2018536697A5 JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5 JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
composition according
protein
homeoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018534025A
Other languages
English (en)
Japanese (ja)
Other versions
JP6860575B2 (ja
JP2018536697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/072675 external-priority patent/WO2017071889A1/en
Publication of JP2018536697A publication Critical patent/JP2018536697A/ja
Publication of JP2018536697A5 publication Critical patent/JP2018536697A5/ja
Application granted granted Critical
Publication of JP6860575B2 publication Critical patent/JP6860575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018534025A 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質 Active JP6860575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482 2015-09-23
EP15306482.9 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2018536697A JP2018536697A (ja) 2018-12-13
JP2018536697A5 true JP2018536697A5 (cg-RX-API-DMAC7.html) 2019-09-05
JP6860575B2 JP6860575B2 (ja) 2021-04-14

Family

ID=54207439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534025A Active JP6860575B2 (ja) 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質

Country Status (8)

Country Link
US (2) US20190247461A1 (cg-RX-API-DMAC7.html)
EP (2) EP3960195B1 (cg-RX-API-DMAC7.html)
JP (1) JP6860575B2 (cg-RX-API-DMAC7.html)
CN (1) CN108289929A (cg-RX-API-DMAC7.html)
CA (1) CA2999209A1 (cg-RX-API-DMAC7.html)
ES (2) ES2895154T3 (cg-RX-API-DMAC7.html)
PL (2) PL3960195T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017071889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024149784A1 (en) 2023-01-13 2024-07-18 Brainever Stabilized engrailed protein aqueous compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) * 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
EP2454597A1 (en) * 2009-07-13 2012-05-23 The University of Surrey Therapeutic peptides, polypeptides ans nucleic acid sequences
WO2013128239A1 (en) 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Similar Documents

Publication Publication Date Title
JP2019524822A5 (cg-RX-API-DMAC7.html)
WO2017070647A8 (en) Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma)
HRP20191055T1 (hr) Terapeutska sredstva za neurodegenerativne bolesti
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
EP3405215A4 (en) METHOD FOR THE TREATMENT OF MORBUS DANON AND OTHER AUTOPHAGIC DISEASES
WO2014178931A8 (en) Sobetirome in the treatment of myelination diseases
SG11201705986QA (en) Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
EA201991756A1 (ru) Бисгетероарильные производные в качестве модуляторов агрегации белков
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2018004109A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
IL278813A (en) Gene therapy for Alzheimer's disease
HK1210598A1 (en) Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
EP3982819A4 (en) METHODS FOR EVALUATION AND TREATMENT OF ALZHEIMER'S DISEASE AND APPLICATIONS THEREOF
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
JP2016523969A5 (cg-RX-API-DMAC7.html)
EA201991753A1 (ru) Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков
JP2018536697A5 (cg-RX-API-DMAC7.html)
WO2019070727A3 (en) Nonviral gene transfer to the suprachoroidal space
PH12021550090A1 (en) Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof
WO2017079161A3 (en) Treatment of neurodegenerative disease with sodium chlorite